Search

Displaying results 3251 - 3260 of 8010 in total
  1. Drug

    Miocamycin

    go.drugbank.com/drugs/DB13287
    Approved

    This drug may be marketed in Japan for clinical use as it is listed in the Japanese pharmacopeia [L5737]. … has shown to be effective against several gram-positive and gram-negative microbes and may be useful in the treatment of upper and lower respiratory tract infections, and urogenital tract infections or

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  2. Drug

    Vadadustat

    go.drugbank.com/drugs/DB12255
    ApprovedInvestigational

    [A244145,A244155] It was first approved in Japan in 2020,[L50371] and in April 2023, it was approved by the EMA for the treatment of symptomatic anemia associated with CKD in adults on chronic maintenance … [A244165] A relatively new and alternative treatment option for patients with anemia associated with CKD is the use of small molecule inhibitors of hypoxia-inducible factor prolyl-hydroxylase (HIF-PH

  3. Drug

    Methapyrilene

    go.drugbank.com/drugs/DB04819
    ApprovedWithdrawn

    Manufacturers voluntarily withdrew methapyriline drug products from the market in May and June 1979.

    Categories: Antihistamines for Systemic Use
  4. Drug

    Citatuzumab Bogatox

    go.drugbank.com/drugs/DB06072
    Investigational

    VB6-845 is a humanized antibody fragment targeting EpCAM fused with the deimmunized form of the cytotoxin Bouganin and is designed for systemic use against metastatic cancer.

  5. Drug

    Sinecatechins

    go.drugbank.com/drugs/DB01266
    ApprovedInvestigationalNutraceutical

    Sinecatechins is a botanical drug product for topical use. … The remaining amount of the drug substance contains undefined botanical constituents derived from green tea leaves.

  6. Drug

    Abaloparatide

    go.drugbank.com/drugs/DB05084
    ApprovedInvestigational

    [L740] It was first approved by the FDA on April 28, 2017,[A256748] for the treatment of osteoporosis in postmenopausal women and is also used to increase bone density in men with osteoporosis. … [L740] In October 2022, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended abaloparatide be granted marketing authorization in Europe [L43552] and the drug was fully authorized

  7. Drug

    MK-8189

    go.drugbank.com/drugs/DB19153
    Investigational

    MK-8189 is under investigation in clinical trial NCT04624243 (Efficacy and Safety of MK-8189 in Participants With an Acute Episode of Schizophrenia (MK-8189-008)).

  8. Drug

    Silicon

    go.drugbank.com/drugs/DB12982
    Approved

    Silicon is under investigation in clinical trial NCT00103246 (Photodynamic Therapy Using Silicon Phthalocyanine 4 in Treating Patients With Actinic Keratosis, Bowen's Disease, Skin Cancer, or Stage I or

    Mixtures: Swical Extra-fort, BLACKMORES teen multi for GIRLS capsule
  9. Drug

    Flucytosine

    go.drugbank.com/drugs/DB01099
    ApprovedInvestigational

    A fluorinated cytosine analog that is used as an antifungal agent.

    Categories: Antifungals for Topical Use, Antimycotics for Systemic Use
  10. Drug

    Tianeptine

    go.drugbank.com/drugs/DB09289
    Investigational

    Asia (including Singapore) and Latin America as “Stablon” and “Tatinol” but it is not available in Australia, Canada, New Zealand, the U.K. or the U.S. … Tianeptine was discovered and patented by The French Society of Medical Research in the 1960s [L2946].